GlaxoSmithKline (GSK -0.2%) says regulatory approval for its H5N1 bird flu vaccine has been...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK -0.2%) says regulatory approval for its H5N1 bird flu vaccine has been delayed. The company blamed the setback on a "recently rectified administrative matter" and says it is working closely with the FDA to ensure the review will be wrapped up as soon as possible.